- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06081400
Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting (CRYODESMO-02)
A Phase II Multicentric, Randomized Trial Assessing Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
"Wait & see" is currently the standard of care of recently diagnosed desmoid tumors (DT). In case of progression or symptomatic disease, medical therapy is nowadays widely used including chemotherapy.
Cryoablation has proven to be beneficial for the treatment of large, progressive and symptomatic DT.
This randomized phase II trial aims to compare cryoablation versus medical therapy in DT patients progressing after the "wait & see" period. Moreover, a cross-over design has been anticipated to allow all patients to undergo cryoablation if necessary.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Afshin GANGI, MD,PhD
- Phone Number: 33 0369550304
- Email: afshin.gangi@chru-strasbourg.fr
Study Contact Backup
- Name: Roberto Luigi CAZZATO, MD
- Phone Number: 33 0369550304
- Email: RobertoLuigi.CAZZATO@chru-strasbourg.fr
Study Locations
-
-
-
Bordeaux, France, 33000
- Not yet recruiting
- Service d'Oncologie Médicale, Service de Radiologie Interventionnelle, Institut BERGONNIE
-
Contact:
- Maud TOULMONDE, MD
-
Principal Investigator:
- Maud Toulmonde, MD
-
Caen, France, 14076
- Not yet recruiting
- Service d'Oncologie Médicale, Service de Radiologie Interventionnelle-Centre François BACLESSE
-
Contact:
- Marie-Aude THENINT, MD
-
Principal Investigator:
- Marie-Aude THENINT, MD
-
Dijon, France, 21079
- Not yet recruiting
- Service d'Oncologie Médicale -Centre Georges François LECLERC
-
Principal Investigator:
- Alice HERVIEU, MD
-
Contact:
- Alice HERVIEU, MD
-
Lyon, France, 69373
- Not yet recruiting
- Service d'Oncologie Médicale, Service de Radiologie Interventionnelle-Centre Léon BERARD
-
Contact:
- Mehdi BRAHMI, MD
-
Principal Investigator:
- Mehdi BRAHMI, MD
-
Marseille, France, 13385
- Not yet recruiting
- Service d'Oncologie Médicale, service de Radiologie Interventionnelle,CHU de Marseille, Hopital La Timone
-
Contact:
- Florence DUFFAUD, MD, PhD
-
Principal Investigator:
- Florence DUFFAUD, MD, PhD
-
Nantes, France, 44000
- Not yet recruiting
- Service de Radiologie-CHU de Nantes
-
Contact:
- Arthur DAVID, MD
-
Principal Investigator:
- Arthur DAVID, MD
-
Nice, France, 06189
- Not yet recruiting
- Service d'Oncologie Médicale-Centre Antoine LACASSAGNE
-
Contact:
- Agnès DUCOULOMBIER, MD
-
Principal Investigator:
- Agnès DUCOULOMBIER
-
Rouen, France, 76038
- Not yet recruiting
- Service d'Oncologie Médicale-Centre Henri BECQUEREL
-
Contact:
- Cécile GUILLEMET, MD
-
Principal Investigator:
- Cécile GUILLEMET, MD
-
Saint-Herblain, France, 44805
- Not yet recruiting
- Service d'Oncologie Médicale
-
Contact:
- Emmanuelle BOMPAS, MD
-
Principal Investigator:
- Emmnauelle BOMPAS, MD
-
Strasbourg, France, 67033
- Recruiting
- Institut de cancerologie Strasbourg Europe (ICANS)
-
Contact:
- Jean-Emmanuel KURTZ, MD PhD
-
Principal Investigator:
- Jean-Emmanuel KURTZ
-
Sub-Investigator:
- Sophie MARTIN
-
Strasbourg, France, 67091
- Recruiting
- Service d'Imagerie Interventionnelle, Hôpitaux Universitaires de Strasbourg , France, 67091
-
Contact:
- Afshin GANGI, MD, PhD
-
Principal Investigator:
- Afshin GANGI, MD, PhD
-
Sub-Investigator:
- Roberto Luigi CAZZATO, MD
-
Sub-Investigator:
- Julien GARNON, MD PhD
-
Toulouse, France, 31059
- Not yet recruiting
- Service d'Oncologie Médicale-Institut Claudius Régaud et Service de Radiologie Interventionnelle, CHU de Toulouse
-
Principal Investigator:
- Thibaud VALENTIN, MD
-
Contact:
- Thibaud VALENTIN, MD
-
Villejuif, France, 94800
- Not yet recruiting
- Service d'Oncologie médicale, Service de Radiologie Interventionnelle- Institut Gustave ROUSSY
-
Contact:
- Frédéric DESCHAMPS, MD
-
Principal Investigator:
- Frédéric DESCHAMPS, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject (male or female) with extra-peritoneal desmoid tumor (confirmed by prior biopsy by an experienced pathologist within the RRePS network)
- 13 years of age or older
- Measurable viable tumor (according to the mRECIST criteria using MRI. The baseline MRI imaging is mandatory in the 2 months prior to treatment initiation (D0).
- Progressive disease (according to the mRECIST criteria) after the watchful waiting period or significant increase in symptoms requiring an active therapy, as advised in a multidisciplinary sarcoma tumor board
- Tumor deemed accessible for cryoablation procedure by the operator in a type I center. (In pediatric cases, a careful site tumor analysis will be performed with interventional radiologist to ensure for limited consequence of cryoablation in pediatric patients especially regarding growth plates).
- 100 % of destruction of the tumor achievable in one procedure of cryoablation with 1cm security margin according to assessment by referral center (type 1) for cryoablation
- ECOG performance status 0-2 at inclusion visit
- Biological and hematological parameters (neutrophils ≥ 1,5.109/L ; platelet count ≥ 100.109/L ; no significant hemostatic abnormalities) in the 4 weeks prior to treatment initiation (D0)
- Subject able to understand the objectives and risks of the research and to give dated and signed informed consent. For minors, the consent of the 2 parents must be obtained.
- Subject affiliated to a social health insurance plan
- For a woman of childbearing age: negative blood pregnancy test at screening/inclusion visit
- Subject agreeing to use a contraceptive method:
Exclusion criteria:
- Intra-peritoneal desmoid tumor
- Known hypersensitivity to vinorelbine or other vinca-alkaloids, or other constituents to navelbine, to vinblastine, to methotrexate or any excipients, current or recent (within 2 weeks) severe infection, severe renal failure, severe hepatic injury, chronic respiratory failure, concomitant treatment with: yellow fever vaccine, prophylactic treatment with phenytoin, trimethoprim, probenecid, acetylsalicylic acid, phenylbutazone.
- Any contra-indication for the procedure as stated by the interventional radiologist in terms of tumor size, proximity to neural/vascular structures or adjacent organs at risk making the procedure at unacceptable risk
- Impaired hemostasis, that may interfere with the conduct of the cryoablation
- Concurrent participation in other experimental studies that could affect endpoints of the present study
- Concurrent use of any antitumor agent or NSAIDs, penicillins, PPIs, acitretin, ciprofloxacin, azote protoxide
- Contraindication to any form of sedation
- Hypersensitivity to gadoteric acid, meglumine or any drug containing gadolinium
- Others contra-indications to MRI
- Pregnancy or breastfeeding
- Impossibility to give the subject informed information (subject in an emergency situation, patient with comprehension difficulties ...)
- Psychiatric disorders
- Incompetent subject (subject to a legal protection measure: curatorship, guardianship, future protection mandate, family habilitation)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cryoablation
One single cryoablation of the desmoid tumor at Day 0
|
Percutaneous imaging-guided cryoablation
|
Active Comparator: Medical therapy
Chemotherapy: at the investigator's discretion: either
|
Either : methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of non-progressive disease
Time Frame: 12 months after treatment initiation (Day 0+12months)
|
Rates of non-progressive disease (sum of complete response (CR), partial response (PR), and stable disease (SD) according to modified RECIST criteria)
|
12 months after treatment initiation (Day 0+12months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival 1
Time Frame: from treatment initiation to PD or 24 months whichever comes first
|
Progression-free survival 1 (PFS1: from the beginning of cryoablation or medical therapy to first disease progression) in cryoablation and medical therapy group
|
from treatment initiation to PD or 24 months whichever comes first
|
Rate of patients who cross over to the other arm
Time Frame: 24 months after treatment initiation
|
24 months after treatment initiation
|
|
Rate of complete response
Time Frame: 12 months after treatment initiation and 12 months after cross-over
|
Rate of complete response at 12 months in cryoablation and medical therapy group with and without a cross-over treatment
|
12 months after treatment initiation and 12 months after cross-over
|
Secondary Progression-free survival 2
Time Frame: Through study completion, up to 39 months
|
Secondary Progression-free survival 2 (PFS 2: from the cross-over to second disease progression) in cryoablation and medical therapy group
|
Through study completion, up to 39 months
|
Incidence of Treatment-Emergent Adverse Events as assessed by NCI-CTCAE version 5.0 toxicity scale
Time Frame: Through study completion, up to 39 months
|
The occurrence of complications and adverse reactions according to the classification of the NCI-CTCAE version 5.0 toxicity scale
|
Through study completion, up to 39 months
|
QUALITY OF LIFE assessed by EUROQOL EQ 5D before and after treatment
Time Frame: Screening visit, Month 1, Month 2, Month 3, Month 6, Month 9 and Month 12 after treatment initiation
|
EUROQOL EQ 5D will be used; score ranging from 1 (good quality of life) to 5 (poor quality of life)
|
Screening visit, Month 1, Month 2, Month 3, Month 6, Month 9 and Month 12 after treatment initiation
|
PAIN assessed by brief pain inventory (BPI) before and after treatment
Time Frame: Screening visit, Day 0/Day 1, Month 1, Month 2, Month 3, Month 6, Month 9 and Month 12 after treatment initiation
|
BPI will be used; score ranging from 0 (no pain) to 10 (high pain)
|
Screening visit, Day 0/Day 1, Month 1, Month 2, Month 3, Month 6, Month 9 and Month 12 after treatment initiation
|
Health economics assessment
Time Frame: Through study completion, up to 39 months
|
cost and incremental cost utility ratio
|
Through study completion, up to 39 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Afshin GANGI, MD, PhD, Hôpitaux Universitaires de Strasbourg
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7361 (IRB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Desmoid Tumor
-
Rabin Medical CenterCompletedDesmoid Fibromatosis | Desmoid | Desmoid Fibromatosis of Skin | Desmoid Neoplasm of Chest Wall | Desmoid Tumor Caused by Somatic Mutation | Aggressive Fibromatoses | Fibromatosis DesmoidIsrael
-
Italian Sarcoma GroupCompletedAdvanced Desmoid Tumor | Advanced ChondrosarcomaItaly
-
Blokhin's Russian Cancer Research CenterNot yet recruitingDesmoid Fibromatosis | Desmoid Tumor | DesmoidRussian Federation
-
Ayala Pharmaceuticals, Inc,Active, not recruitingDesmoid Tumor | DesmoidUnited States, Spain, United Kingdom, Australia, Korea, Republic of, Israel, Belgium, Germany, Netherlands, Italy, Poland
-
University of Colorado, DenverSpringWorks Therapeutics, Inc.No longer availableNeoplasm | Desmoid TumorUnited States
-
Erasmus Medical CenterRadboud University Medical Center; Royal Marsden NHS Foundation Trust; The Netherlands...CompletedDesmoid Tumor | Desmoid-type FibromatosisUnited Kingdom, Netherlands
-
Technische Universität DresdenUniversitätsmedizin Mannheim; SOS Desmoid e.V.RecruitingQuality of Life | Desmoid TumorGermany
-
University Hospital, Strasbourg, FranceRecruiting
-
MaineHealthPfizer; Desmoid Tumor Research FoundationCompleted
Clinical Trials on Cryoablation
-
Boston Scientific CorporationTerminated
-
Boston Scientific CorporationTerminatedPain | Pancreatic CancerUnited States
-
Mayo ClinicRecruitingPrimary Malignant Neoplasm of Prostate (Diagnosis)United States
-
Boston Scientific CorporationCompletedPain | Neoplasm MetastasisUnited States, Canada, France
-
Boston Scientific CorporationCompletedMetastatic Lung CancerUnited States, France
-
afreeze GmbHAccovion GmbHTerminatedPathologic Processes | Heart Diseases | Cardiovascular Diseases | Arrhythmias, Cardiac | Atrial Fibrillation (Paroxysmal)Austria, Germany, Switzerland
-
Boston Scientific CorporationWithdrawn
-
Boston Scientific CorporationCompletedNeoplasm MetastasisUnited States, France
-
Boston Scientific CorporationCompletedPain | Neoplasm Metastasis | Bone Metastasis of Diverse OriginsUnited States, France
-
Shanghai 10th People's HospitalNot yet recruitingHypertension | Paroxysmal Atrial FibrillationChina